Announcements Trials
Browse Landscape

Phase

Phase 4 4Phase 2 4Phase 3 3

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Breast Neoplasms 1129Carcinoma, Non-Small-Cell Lung 718Neoplasms 546Prostatic Neoplasms 505Colorectal Neoplasms 439Multiple Myeloma 338Lung Neoplasms 310Neoplasm Metastasis 289Leukemia, Myeloid, Acute 263Stomach Neoplasms 248Carcinoma, Hepatocellular 246Ovarian Neoplasms 225Rectal Neoplasms 211Colonic Neoplasms 204Lymphoma, Follicular 200Lymphoma 199Leukemia 190Uterine Cervical Neoplasms 181Head and Neck Neoplasms 174Pancreatic Neoplasms 172Lymphoma, Non-Hodgkin 167Leukemia, Lymphocytic, Chronic, B-Cell 166Lymphoma, Large B-Cell, Diffuse 163Recurrence 162Melanoma 158Precursor Cell Lymphoblastic Leukemia-Lymphoma 154Squamous Cell Carcinoma of Head and Neck 147Pain 141Urinary Bladder Neoplasms 139Brain Neoplasms 133

Interventions

rasburicase 2Allopurinol 2Urate Oxidase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Interventional × Hyperuricemia × Clear all
NCT00921375 2014-12-12

Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated Hyperuricemia

Virchow Group

Phase 3 Completed
100 enrolled

Hyperuricemia

NCT00607152 2014-05-08

Rasburicase (Fasturtec) Registration Trial

Sanofi

Phase 3 Terminated
10 enrolled

Hyperuricemia

NCT00230178 2010-01-12

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Sanofi

Phase 3 Completed
280 enrolled 10 charts
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Neoplasms, Tumor Lysis Syndrome, Hyperuricemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡